In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F23%3A43925984" target="_blank" >RIV/00064173:_____/23:43925984 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/23:43925984 RIV/75010330:_____/23:00014406
Result on the web
<a href="https://doi.org/10.1089/mdr.2023.0090" target="_blank" >https://doi.org/10.1089/mdr.2023.0090</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1089/mdr.2023.0090" target="_blank" >10.1089/mdr.2023.0090</a>
Alternative languages
Result language
angličtina
Original language name
In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
Original language description
The objective of this study was to assess the susceptibility of cefiderocol against multidrug-resistant carbapenemase-producing and nonproducing bacteria. The panel comprised 182 isolates of the order Enterobacterales, and 40 strains of Pseudomonas aeruginosa. Antimicrobial susceptibility testing has been performed using broth microdilution method according to the European Committee on Antimicrobial Susceptibility Testing recommendations. Mass spectrometry matrix-assisted laser desorption/ionization-time of flight mass spectrometry and carbapenemase-producing test were used to verify the presence of carbapenemases in clinical isolates. The genetic expression of single carbapenemases (bla(KPC), bla(OXA-48), bla(NDM), bla(VIM), bla(IMP), bla(GES)) was determined by real-time polymerase chain reaction. Cefiderocol exhibited a good activity against the majority of strains tested in this study. Altogether, growth of 81.9% (n = 149) strains of the order Enterobacterales and 77.5% (n = 31) of P. aeruginosa isolates were inhibited at minimal inhibitory concentration (MIC) <=2 mg/L. Values MIC(50)/MIC(90) were 0.5/8 mg/L for enterobacteria, and 1/8 mg/L for P. aeruginosa. One isolate (Klebsiella pneumoniae) harboring two carbapenemases (bla(OXA-48), bla(NDM)) had cefiderocol MIC 0.5 mg/L. In enterobacteria resistant to cefiderocol, bla(NDM) carbapenemase prevailed (43.3%, n = 29), followed by bla(OXA-48) (31.3%, n = 21) and bla(KPC) (4.5%, n = 3). bla(IMP) (n = 8) and bla(VIM) (n = 1) metallo-β-lactamases dominated in cefiderocol-resistant P. aeruginosa (n = 9) isolates. Very good susceptibility (100%) to this drug showed bla(GES)-positive strains of P. aeruginosa (n = 8) and isolates resistant to meropenem without confirmed carbapenemase gene (n = 10). In this study, cefiderocol demonstrated potent activity against important nosocomial pathogens, therefore, therapeutic options of this drug against multidrug-resistant bacteria should be considered.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30304 - Public and environmental health
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Microbial Drug Resistance
ISSN
1076-6294
e-ISSN
1931-8448
Volume of the periodical
290
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
485-491
UT code for WoS article
001085013900006
EID of the result in the Scopus database
2-s2.0-85170686816